AEGON ASSET MANAGEMENT UK Plc Sells 26,554 Shares of Insulet Co. (NASDAQ:PODD)

AEGON ASSET MANAGEMENT UK Plc decreased its position in Insulet Co. (NASDAQ:PODD - Free Report) by 20.7% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 101,806 shares of the medical instruments supplier's stock after selling 26,554 shares during the period. AEGON ASSET MANAGEMENT UK Plc owned about 0.14% of Insulet worth $26,713,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the company. SBI Securities Co. Ltd. acquired a new position in Insulet during the fourth quarter worth $36,000. Itau Unibanco Holding S.A. bought a new stake in Insulet during the 4th quarter worth about $42,000. SRS Capital Advisors Inc. boosted its stake in shares of Insulet by 43.1% during the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock worth $49,000 after buying an additional 56 shares during the last quarter. Assetmark Inc. grew its holdings in shares of Insulet by 1,447.1% in the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after acquiring an additional 246 shares in the last quarter. Finally, Blue Trust Inc. increased its position in shares of Insulet by 117.3% in the fourth quarter. Blue Trust Inc. now owns 276 shares of the medical instruments supplier's stock valued at $72,000 after acquiring an additional 149 shares during the last quarter.

Analyst Ratings Changes

A number of research firms have weighed in on PODD. The Goldman Sachs Group began coverage on Insulet in a research note on Friday, May 30th. They issued a "buy" rating and a $380.00 price target for the company. Royal Bank of Canada started coverage on shares of Insulet in a research note on Thursday, March 6th. They issued an "outperform" rating and a $340.00 target price for the company. Raymond James restated an "outperform" rating and set a $360.00 target price (up from $328.00) on shares of Insulet in a report on Tuesday, May 27th. Wells Fargo & Company set a $322.00 price target on shares of Insulet in a research note on Monday, April 28th. Finally, Canaccord Genuity Group boosted their price objective on shares of Insulet from $304.00 to $324.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Three investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $318.41.

Insulet Stock Performance

NASDAQ PODD traded down $2.05 on Thursday, reaching $317.16. The stock had a trading volume of 902,220 shares, compared to its average volume of 709,281. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The company has a market cap of $22.32 billion, a P/E ratio of 54.78, a price-to-earnings-growth ratio of 3.62 and a beta of 1.37. The firm has a fifty day moving average of $280.28 and a two-hundred day moving average of $272.91. Insulet Co. has a 1-year low of $173.00 and a 1-year high of $329.33.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, topping analysts' consensus estimates of $0.81 by $0.21. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The business had revenue of $569.00 million for the quarter, compared to analyst estimates of $543.20 million. During the same period last year, the firm earned $0.73 earnings per share. Insulet's revenue for the quarter was up 28.8% compared to the same quarter last year. On average, equities research analysts anticipate that Insulet Co. will post 3.92 EPS for the current year.

Insider Activity

In other news, SVP John W. Kapples sold 5,278 shares of the business's stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the transaction, the senior vice president now directly owns 23,180 shares in the company, valued at approximately $7,382,134.60. The trade was a 18.55% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Wayne A.I. Frederick sold 1,825 shares of the company's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the sale, the director now directly owns 3,231 shares of the company's stock, valued at approximately $888,525. This trade represents a 36.10% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is owned by company insiders.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.